Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The country’s strength lies not just in technology availability but in adoption behaviour
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Access to genomic testing, not therapy cost, is the biggest challenge
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Subscribe To Our Newsletter & Stay Updated